Key takeaways
- Low testosterone reduces muscle mass, lowers resting energy expenditure and shifts adipocyte biology toward storage.
- Where central obesity is substantial and testosterone only borderline, fat loss frequently raises testosterone without it ever being treated.
- Each step makes the next step slightly easier, which is what distinguishes a self-reinforcing loop from a simple correlation.
- Testosterone influences body composition through several routes that all point the same way when it falls.
- Visceral adipose tissue in particular is an active endocrine organ, and four of its outputs act directly against testosterone.
A man in his forties notices his waistband moving before he notices anything else. Training has not changed. Diet has not obviously changed. The scale has moved a little, but the shape has moved more. Somewhere in the same window, drive flattened, recovery slowed and sleep got worse. These are usually treated as separate complaints in separate appointments. They are more often one process: fat and testosterone are pushing each other in the same direction, and the loop tightens quietly over years rather than announcing itself.
The loop, stated precisely
Low testosterone makes visceral fat easier to accumulate. Visceral fat makes testosterone harder to maintain. Each step makes the next step slightly easier, which is what distinguishes a self-reinforcing loop from a simple correlation.
The important consequence is about timing rather than mechanism. A loop that gains a small amount of ground each year does not present as a problem at any single point — it presents as a decade in which nothing was ever acutely wrong and the end position is substantially worse than the start. That is why this is one of the dominant mechanisms of midlife metabolic decline, and why the intervention that works is usually the one applied to both arms at once rather than the strongest single agent.
Side one: what low testosterone does to fat storage
Testosterone influences body composition through several routes that all point the same way when it falls.
- Muscle mass falls, and with it resting energy expenditure. Muscle is metabolically expensive tissue. Losing it lowers the daily energy budget without any change in behaviour, so the same intake becomes a small surplus.
- Adipocyte differentiation shifts. Testosterone influences whether mesenchymal precursor cells commit toward muscle or toward fat. Lower androgen signalling favours the fat side of that fork.
- Activity drops without a decision being made. Reduced drive and energy show up as fewer steps, shorter sessions, less spontaneous movement. This is rarely reported as a symptom because it does not feel like one.
- Lipolysis slows in some depots. Mobilising stored fat becomes marginally harder, particularly abdominally.
- Insulin signalling worsens. Lower testosterone is associated with poorer insulin sensitivity independent of weight, which biases the system toward storage — testosterone and insulin sensitivity covers that link on its own.
Side two: what visceral fat does to testosterone
Adipose tissue is not inert storage. Visceral adipose tissue in particular is an active endocrine organ, and four of its outputs act directly against testosterone.
- Aromatase. Adipose tissue expresses aromatase, the enzyme that converts testosterone to estradiol. More fat means more conversion. The resulting estradiol feeds back at the hypothalamus and pituitary to suppress LH output, which reduces the signal telling the testes to produce testosterone in the first place (Cohen, Med Hypotheses 2001). Aromatase covers the enzyme in more detail.
- Inflammatory cytokines. IL-6 and TNF-α produced by adipose tissue suppress Leydig cell steroidogenesis directly. This is a testicular effect rather than a central one, which is why the pattern often shows low testosterone without the high LH that primary testicular failure would produce.
- Reduced SHBG. Hyperinsulinaemia, driven by the insulin resistance that tracks visceral fat, lowers sex hormone binding globulin. Total testosterone falls as a result, and interpreting that number without SHBG in front of you produces the wrong conclusion — see SHBG explained.
- Sleep apnoea. Central obesity substantially raises the risk of obstructive sleep apnoea, and fragmented sleep suppresses the nocturnal testosterone rise that produces the morning peak (Luboshitzky et al., J Clin Endocrinol Metab 2001). This one is frequently the largest single contributor and the most commonly missed.
Why the visceral compartment specifically
Subcutaneous fat and visceral fat are not the same tissue doing the same job in different places. Visceral fat is more metabolically active, more inflammatory, more lipolytically responsive, and it drains into the portal vein — meaning its free fatty acid and cytokine output arrives at the liver first and at higher concentration than anything released from a thigh.
That is why waist circumference tracks metabolic risk better than weight, and why a man can be within a normal BMI and still sit squarely inside this loop. It is also why the scale is a poor instrument here: replacing muscle with visceral fat can leave body weight almost unchanged while every marker that matters moves in the wrong direction.
What treatment actually moves, and how fast
Testosterone therapy in men with confirmed hypogonadism reduces visceral fat by roughly 10-20% over one to two years, reduces total fat mass more modestly at around 3-6%, and increases lean mass by something in the range of 5-15%. Body composition consistently changes more than scale weight does, because the two are moving in opposite directions (Wittert et al., Lancet Diabetes Endocrinol 2021).
The timeline is worth setting out honestly, because expectations set from the internet are usually wrong. Energy and mood tend to shift within the first several weeks. Body composition change is slow and mostly invisible for the first three months, becomes measurable somewhere around six months, and continues out to eighteen months or two years before plateauing. Anyone judging the result at week eight is judging the wrong endpoint. And the common early experience of weight going up is usually water and lean mass rather than fat — why am I gaining weight on TRT covers that.
The blunt version: testosterone therapy is a muscle-and-metabolism intervention that reduces fat as a downstream effect. It is not a fat-loss drug, and framing it as one sets up a disappointment that the treatment did not cause.
Which arm to break first
Because the loop runs in both directions, there is a genuine decision about where to intervene, and it is not the same answer for everyone.
| Situation | Where the leverage usually is |
|---|---|
| Confirmed low testosterone, modest central fat | Treat the hormone side and load the muscle; fat follows |
| Substantial central obesity, borderline testosterone | Fat loss first — testosterone frequently rises without ever being treated |
| Both clearly abnormal | Both arms together; single-agent approaches tend to stall |
| Snoring, unrefreshing sleep, morning headache | Investigate sleep apnoea before concluding anything about hormones |
The second row is the one most often skipped. Weight loss of any meaningful size raises endogenous testosterone in men with obesity-associated hypogonadism, because it removes the aromatase load, the inflammatory load and often the apnoea at the same time. A man who has never attempted that has not yet established that he needs hormone therapy at all.
The clinical pearl: the two most common errors here are opposites. One is treating the testosterone number and ignoring the fat that is suppressing it, which produces a good lab value inside an unchanged metabolic picture. The other is pursuing fat loss without resistance training, which strips the muscle that was holding the whole system up. Neither arm holds on its own.
What is worth measuring
Weight is the least informative number available in this situation. More useful: waist circumference, as a crude proxy for the visceral compartment; total and free testosterone with SHBG, since total alone is uninterpretable when insulin is high; fasting insulin and HbA1c; a sensitive estradiol assay, given how much aromatase activity is in play; and haematocrit if hormone therapy is being considered. Strength benchmarks are the simplest honest readout of whether lean tissue is being held while anything else changes.
Bottom line
Testosterone and visceral fat reinforce each other through aromatase, inflammatory signalling, SHBG suppression and disrupted sleep, and the loop is slow enough that it rarely presents as an event. Testosterone therapy reduces visceral fat meaningfully but slowly, and it works on the muscle and metabolic side rather than acting as a fat-loss agent. For a man with both central obesity and confirmed low testosterone, treating one arm usually produces a modest result and treating both usually produces a different-looking person. The non-negotiable component in every version of this is progressive resistance training with enough protein to use it, because that is the part that determines whether the weight lost is fat rather than the muscle that was keeping the loop from tightening further. Whether treatment is appropriate is a physician's call after labs — the 60-second assessment is where that starts.
Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.
